Zacks Research Issues Positive Forecast for Sanofi Earnings

Sanofi (NASDAQ:SNY) – Research analysts at Zacks Research increased their Q2 2027 earnings per share estimates for Sanofi in a research report issued on Monday, November 10th. Zacks Research analyst Team now expects that the company will post earnings of $1.20 per share for the quarter, up from their previous estimate of $1.18. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q3 2027 earnings at $1.46 EPS and FY2027 earnings at $5.08 EPS.

A number of other equities research analysts also recently issued reports on SNY. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Wednesday, November 5th. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $62.67.

Sanofi Price Performance

SNY traded up $0.66 during trading hours on Wednesday, hitting $52.35. The company’s stock had a trading volume of 40,627 shares, compared to its average volume of 2,704,010. The stock has a market cap of $128.54 billion, a price-to-earnings ratio of 12.24, a P/E/G ratio of 1.38 and a beta of 0.49. The business’s 50-day moving average price is $48.70 and its 200-day moving average price is $49.43. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.10. The business had revenue of $14.53 billion during the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s revenue for the quarter was down 7.5% compared to the same quarter last year. During the same quarter last year, the business posted $2.25 EPS.

Institutional Trading of Sanofi

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its stake in shares of Sanofi by 1.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company’s stock valued at $612,106,000 after acquiring an additional 193,196 shares during the period. Raymond James Financial Inc. boosted its position in shares of Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares during the period. Franklin Resources Inc. raised its holdings in shares of Sanofi by 9.9% in the 2nd quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after buying an additional 384,902 shares during the period. Federated Hermes Inc. lifted its stake in Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after acquiring an additional 1,456,269 shares in the last quarter. Finally, Mondrian Investment Partners LTD acquired a new position in Sanofi in the 3rd quarter valued at about $171,742,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.